Swedish pharma firm AlzeCure Pharma adds Dr. Jan Lundberg, former Eli Lilly R&D head, as investor and board member for CNS disease expertise.
Swedish pharma firm AlzeCure Pharma, focusing on CNS diseases, announces Dr. Jan Lundberg, ex-global head of R&D at Eli Lilly, as investor and proposed board member. Lundberg, with experience in developing 200 drug candidates and 30 approved products, will offer his expertise in CNS diseases to AlzeCure. The company is developing drugs for Alzheimer's, pain, and other CNS diseases.
April 10, 2024
4 Articles